Leukapheresis

Data presented at EULAR 2024 suggest that there are positive times ahead for the treatment of SLE, with experts encouraged but cautious about what the future holds.

High overall response rate, even though many were ineligible for trial leading to drug's approval

Stunning improvement for two patients with rare form of autoimmune myositis

Recent findings yield good news about bridging the urban-rural healthcare gap.

More than half of patients achieved complete responses with lisocabtagene maraleucel

Six CAR-T-cell therapies have been approved by the European Commission and the US FDA, and other T-cell therapies are being developed.

Final results from a phase 3 trial with the investigational DCVax-L vaccine show that overall survival was increased both in patients with newly diagnosed glioblastoma as well as recurrent disease.

Durable response possible with treatment targeting a different antigen

Promising results from small case studies and early clinical trials hint at the potential of CAR-T cell therapy to treat -- and possibly cure -- autoimmune diseases like lupus.

Patients in pilot study show months-long complete remission

Supply shortages and limited manufacturing capacity are leaving myeloma patients waiting months for CAR T-cell therapy, which offers a "last chance" after all other therapies have failed.